Kinetic Concepts, Inc. Closes Private Sale of Convertible Senior Notes Due 2015 Pursuant to Full Exercise of Over-Allotment Option

Kinetic Concepts, Inc. (NYSE:KCI) today announced the closing of the private sale of an additional $90 million aggregate principal amount of its 3.25% convertible senior notes due 2015 pursuant to the exercise in full of the over-allotment option granted to the initial purchases of the notes. This brings the total amount of the notes issued to $690 million. The coupon on the notes is 3.25% per year on the principal amount. Interest will accrue from April 21, 2008, and is payable semi-annually in arrears on April 15 and October 15 of each year, beginning October 15, 2008. The notes will mature on April 15, 2015, unless previously converted or repurchased in accordance with their terms. The notes are not redeemable by KCI prior to the maturity date. Upon conversion, holders will receive cash up to the aggregate principal amount of the notes being converted and shares of KCI common stock in respect of the remainder, if any, of KCI’s conversion obligation in excess of the aggregate principal amount of the notes being converted. The initial conversion rate for the notes is 19.4764 shares of KCI common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $51.34 per share of common stock and represents a 27.5% conversion premium over the last reported sale price of KCI’s common stock on April 15, 2008 (the day of pricing of the notes), which was $40.27 per share. The conversion rate and the conversion price will be subject to adjustment in certain events, such as distributions of dividends or stock splits. In connection with the sale of the additional notes, KCI entered into additional convertible note hedge transactions with financial institutions that are affiliates of two of the offering's initial purchasers for the purpose of reducing the potential dilution upon future conversion of the notes. KCI also entered into additional warrant transactions with the same counterparties. In the event the price of KCI’s common stock at exercise exceeds $60.41 per share, which is approximately 50% higher than the closing price of KCI’s common stock on April 15, 2008, the warrant transaction will have a dilutive effect on KCI’s earnings per share. At expiration, the warrants will be settled in shares or, subject to certain conditions, in cash at our election. KCI intends to use a portion of the net proceeds from the sale of the additional notes to pay the estimated cost of the additional convertible note hedge transactions, taking into account the proceeds to KCI from the additional warrant transactions, and to use the balance of the net proceeds to fund a portion of the purchase price of the proposed acquisition of LifeCell Corporation, repay certain indebtedness of KCI, provide ongoing working capital and provide for other general corporate purposes of the combined company. KCI has been advised that, in connection with establishing their initial hedge of the convertible note hedge and warrant transactions entered into in connection with the initial sale of notes and in connection with the sale of the additional notes, KCI’s counterparties or their affiliates entered into various derivative transactions with respect to KCI common stock. KCI has been further advised that its counterparties or their affiliates may modify their respective hedge positions by entering into or unwinding various derivative transactions with respect to KCI common stock and/or by purchasing or selling KCI common stock in secondary market transactions during the term of the notes. In particular, such hedge modification transactions are likely to occur during an observation period related to any conversions of the notes, which may have a negative effect on the amount or value of the consideration received in relation to the conversion of those notes. Any of these activities could adversely affect the value of KCI common stock and the value of consideration that holders may receive upon conversion of the notes. The notes and the shares of common stock underlying the notes have not been registered under the Securities Act of 1933, as amended (the "Securities Act”), or any applicable state securities laws, and were offered only to qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act. Unless so registered, the notes may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state. About KCI KCI is a global medical technology company with leadership positions in advanced wound care and therapeutic support systems. We design, manufacture, market and service a wide range of proprietary products that can improve clinical outcomes and can help reduce the overall cost of patient care. Our advanced wound care systems incorporate our proprietary Vacuum Assisted Closure®, or V.A.C.® Therapy technology, which has been demonstrated clinically to promote wound healing through unique mechanisms of action and can help reduce the cost of treating patients with serious wounds. Our therapeutic support systems, including specialty hospital beds, mattress replacement systems and overlays, are designed to address pulmonary complications associated with immobility, to reduce skin breakdown and assist caregivers in the safe and dignified handling of obese patients. We have an infrastructure designed to meet the specific needs of medical professionals and patients across all healthcare settings, including acute care hospitals, extended care organizations and patients' homes, in 19 countries in the United States and abroad. For more information, visit our web site at www.kci1.com. Forward Looking Statements This communication contains forward-looking statements, which may be identified by words such as "believes,” "expects,” "anticipates,” "estimates,” "projects,” "intends,” "should,” "seeks,” "future,” "continue,” or the negative of such terms, or other comparable terminology. Forward-looking statements are subject to risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from those expressed in or indicated by them. Such forward-looking statements include, but are not limited to, statements about KCI’s ability to implement its strategic and business initiatives, including its proposed acquisition of LifeCell Corporation, financial expectations and intentions and other statements that are not historical facts. Additional risks and factors are identified in KCI’s filings with the U.S. Securities Exchange Commission (the "SEC”), including its Report on Form 10-K for the fiscal year ending December 31, 2007, which is available on the SEC’s website at http://www.sec.gov. KCI undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.